Roundhill GLP-1 & Weight Loss ETFOZEM
Type
ETF
Peer group
Global equity
Net assets
$51.4M
Expense ratio
0.59%
1-year return
+27.9%
3 years, a year
—
5 years, a year
—
12-month yield
1.31%
Holdings
27
What it aims to do.
The Fund seeks to provide capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co | 16.10% |
| NVO Novo Nordisk A/S | 13.13% |
| Mount Vernon Liquid Assets Portfolio, LLC | 12.14% |
| PFE Pfizer Inc | 7.56% |
| VKTX Viking Therapeutics Inc | 5.29% |
| Innovent Biologics Inc | 5.10% |
| Ascletis Pharma Inc | 4.67% |
| AMGN Amgen Inc | 3.94% |
| Roche Holding AG | 3.92% |
| AstraZeneca PLC | 3.77% |
More on OZEM.
- OZEM overview
- OZEM holdings
- OZEM risk
- OZEM costs
- OZEM money in and out
- OZEM share classes
- Compare OZEM with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.